PLAINSBORO, N.J. – Wegovy HD (semaglutide) Injection 7.2 mg is now available nationwide, offering the greatest weight loss achieved with any Wegovy injection to date. This new option expands the range of treatments within the Wegovy label, providing American adults living with obesity another tool to help lose weight and maintain it, when used alongside diet and exercise.
"We know that patients are looking for additional options for weight loss, and with Wegovy HD we are answering that call. Whether patients haven't yet reached their weight loss goals on lower-dose Wegovy injectables, or they simply have a more significant amount of weight to lose, the 21% weight loss demonstrated in the STEP UP trial, if all patients stayed on treatment, shows what's possible with this new dose, and that's an opportunity we're excited to provide," said Ed Cinca, senior vice president, Marketing & Patient Solutions at Novo Nordisk. "Additionally, Wegovy is the only weight loss medicine for adults with obesity proven to reduce the risk of events such as stroke, heart attack, or cardiovascular death in those who also have known heart disease. Each dose of Wegovy, including Wegovy HD, will be available nationwide through the channels where patients can access Wegovy, including US pharmacies, select telehealth providers, and more."
Prior to this approval, the highest approved dose of Wegovy injectable for weight loss was 2.4 mg, which is also indicated, along with a reduced calorie diet and increased physical activity, to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight.
